Advancing Stroke Prevention: The Pharmacist’s Role in Implementing the 2024 Guidelines

Program Description

Stroke remains a leading cause of death and disability worldwide, yet many cases are preventable through evidence-based interventions. The 2024 AHA/ASA guidelines for primary stroke prevention introduce significant updates, including a focus on addressing social determinants of health and new pharmacologic strategies like GLP-1 receptor agonists for high-risk patients. This activity equips pharmacists with the latest knowledge to identify and mitigate stroke risk factors, implement effective patient care plans, and enhance adherence to preventive strategies. By participating, pharmacists will gain actionable insights to support healthier outcomes in their communities.

Target audience: Ambulatory Care Pharmacist, Community Pharmacist

Type of activity: Application
Release date: June 9, 2025
Expiration date: June 9, 2026

Time to complete activity: 1.0 hour

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify key updates from the 2024 AHA/ASA guidelines for the primary prevention of stroke and their implications for community pharmacy practice.
• Explain the role of pharmacists in assessing and mitigating stroke risk factors through evidence-based lifestyle and pharmacologic interventions.
• Implement strategies to address social determinants of health and improve adherence to preventive measures among at-risk populations.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-161-H01-P. The activity is available for CE credit through June 9, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Vasyl Zbyrak, PharmD, BCPS, BCACP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms